US 12,344,668 B2
Methods for modulating mannose content of recombinant proteins
Jian Wu, Acton, MA (US); Nicole Sabo, Camarillo, CA (US); Michael De La Cruz, Claremont, CA (US); and Gregory Flynn, Thousand Oaks, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on Sep. 24, 2020, as Appl. No. 17/030,842.
Application 17/030,842 is a division of application No. 15/150,627, filed on May 10, 2016, granted, now 10,829,551.
Application 15/150,627 is a continuation of application No. 13/741,280, filed on Jan. 14, 2013, granted, now 9,359,435, issued on Jun. 7, 2016.
Application 13/741,280 is a continuation of application No. 12/569,830, filed on Sep. 29, 2009, granted, now 8,354,105, issued on Jan. 15, 2013.
Application 12/569,830 is a continuation of application No. 11/644,345, filed on Dec. 22, 2006, abandoned.
Claims priority of provisional application 60/761,477, filed on Jan. 23, 2006.
Prior Publication US 2021/0115125 A1, Apr. 22, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/00 (2006.01); C07K 16/24 (2006.01); C12N 5/00 (2006.01); C12P 21/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/244 (2013.01) [C07K 16/00 (2013.01); C12N 5/0037 (2013.01); C12P 21/005 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/41 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C12N 2500/02 (2013.01); C12N 2500/12 (2013.01); C12N 2500/32 (2013.01); C12N 2500/34 (2013.01); C12N 2500/38 (2013.01); C12N 2500/60 (2013.01); C12N 2500/74 (2013.01); C12N 2500/76 (2013.01)] 6 Claims
 
1. A method of treating celiac disease, comprising administering to a subject a composition comprising an antibody or an antigen-binding fragment thereof,
wherein fewer than about 10% of the antibody or antigen-binding fragment molecules in the composition have more than 4 mannose residues per N-linked oligosaccharide, and
wherein the antibody or antigen-binding fragment thereof comprises:
a light chain variable region comprising the CDRs of the light chain variable region sequence set forth in SEQ ID NO:4, and
a heavy chain variable region comprising the CDRs of the heavy chain variable region sequence set forth in SEQ ID NO:2.